- Home
- Products
- Customized ADCs
- CD74
- Anti-CD74-MCC-Dox ADC
Anti-CD74-MCC-Dox ADC (CAT#: ADC-W-578)
This ADC product is comprised of an anti-CD74 monoclonal antibody conjugated via a MCC linker to DOX. The DOX is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DOX binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD74
- Alternative Names
- CD74; CD74 molecule, major histocompatibility complex, class II invariant chain; II; DHLAG; HLADG; Ia-GAMMA; HLA class II histocompatibility antigen gamma chain; p33; HLA-DR-gamma; MHC HLA-DR gamma chain; Ia-associated invariant chain; gamma chain of clas
- Target Entrez Gene ID
- 972
- Target UniProt ID
- P04233
- Overview
- The protein encoded by this gene associates with class II major histocompatibility complex (MHC) and is an important chaperone that regulates antigen presentation for immune response. It also serves as cell surface receptor for the cytokine macrophage migration inhibitory factor (MIF) which, when bound to the encoded protein, initiates survival pathways and cell proliferation. This protein also interacts with amyloid precursor protein (APP) and suppresses the production of amyloid beta (Abeta). Multiple alternatively spliced transcript variants encoding different isoforms have been identified.
- Overview
- Humanized Anti-CD74 Antibody
- Species Reactivity
- Human
- Name
- MCC (Maleimidomethyl cyclohexane-1-carboxylate)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- doxorubicin
- Description
- Doxorubicin is the generic name for the trade name drug, Adriamycin?, as well as, Rubex?, which is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD3E (Pasotuxizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2425)
- Anti-NGcGM3 (Racotumomab)-SMCC-DM1 ADC (CAT#: ADC-W-2264)
- Anti-NOTCH2 (Tarextumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2221)
- Anti-CD22 (clone RFB4)-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-193)
- Anti-STEAP-1 (clone 120v.24)-Mc-MMAF ADC (CAT#: ADC-W-144)
- Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2570)
- Anti-EGFR (Panitumumab)-MC-MMAF ADC (CAT#: ADC-W-1042)
- Anti-ACVR2B (Bimagrumab)-MC-MMAF ADC (CAT#: ADC-W-652)
- Anti-ITGAV+ITGB3 (Etaracizumab)-SPDB-DM4 ADC (CAT#: ADC-W-2127)
- Anti-CSF2 (Namilumab)-SPDB-DM4 ADC (CAT#: ADC-W-987)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-578. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-2552 | Anti-CD74-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-2548 | Anti-CD74-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-378 | Anti-CD74-hindered disulfide-Doxorubicin ADC | hindered disulfide | doxorubicin |
ADC-W-377 | Anti-CD74 (clone HuMax)-Mc-VC-PABC-MMAF ADC | MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2549 | Anti-CD74-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-618 | Anti-MS4A1-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-606 | Anti-ERBB2-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-527 | Anti-CD79B-MCC-DM1 ADC | Mcc (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-336 | Anti-CD22-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-512 | Anti-ERBB2-SMCC-maytansine ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | maytansine |
CAT# | Product Name | Linker | Payload |
ADC-W-571 | Anti-ERBB2 (Trastuzumab)-DOX ADC | thiomaleamicacids-p-aminobenzyloxycarbonyl | doxorubicin |
ADC-W-503 | Anti-EGFR-EDC/NHS-Dox ADC | EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) | Doxorubicin |
ADC-W-602 | Anti-FOLR1-S-S-Dox ADC | disulfide (“S-S”) linker | doxorubicin |
ADC-W-502 | Anti-EGFR-SMCC-Dox ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | Doxorubicin |
ADC-W-581 | Anti-EpCAM (MOC31)-hydrazone-Doxorubicin ADC | acid-cleavable hydrazone linker | doxorubicin |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.